跳至主要内容
临床试验/DRKS00022948
DRKS00022948招募中不适用

The prospective cohort study on differentiation and treatment of membranous nephropathy by Wenyang Huaji method

Beijing Hospital of Traditional Chinese Medicine0 个研究点目标入组 296 人开始时间: 2020年11月23日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
296

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • ?Conforms to the MN diagnostic criteria.
  • ?Conforms to the diagnostic criteria of Shaoyin Taiyin syndrome.
  • ?The patient has signed the informed consent.
  • ?Between the ages of 18 and 75.
  • ?CKD stage I-III, eGFR>30ml/min, serum albumin >15g/L.

排除标准

  • ?Progressive membranous nephropathy (progressive decrease of renal function;Kidney biopsy showed necrotizing capillaritis and > 50% large crescent), accompanied by IgA nephropathy, diabetic nephropathy and other kidney diseases.
  • ?Confirmed hepatitis B, systemic lupus erythematosus, tumor, drug damage and other factors secondary and need to actively treat the primary disease, such as active hepatitis B and persistent liver function test transaminase abnormalities, or anti-nuclear antibodies, double Abnormal strand DNA, ANCA or other indicators of immune disease.
  • ?With acute central nervous system disease, severe gastrointestinal disease, a history of HIV infection, a history of mental illness or a history of malignancy.
  • ?With other organ diseases and dysfunction, and with life-threatening complications such as severely infected persons.
  • ?Pregnant or lactating women.
  • ?Other clinical trials are under study.

研究者

相似试验